Clinical Trial Update: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports ongoing Phase 1/2 studies evaluating AK109 and AK104 in advanced gastric cancer and gastroesophageal junction adenocarcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK109 (AK109)

Snippet

Sponsor: Akeso | Conditions: Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING